|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang LY, Fang F, Ou DP, Wu W, Zeng ZJ and
Wu F: Solitary large hepatocellular carcinoma: A specific subtype
of hepatocellular carcinoma with good outcome after hepatic
resection. Ann Surg. 249:118–123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aravalli RN, Cressman EN and Steer CJ:
Cellular and molecular mechanisms of hepatocellular carcinoma: An
update. Arch Toxicol. 87:227–247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Farazi PA and DePinho RA: Hepatocellular
carcinoma pathogenesis: From genes to environment. Nat Rev Cancer.
6:674–687. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hong W and Guan KL: The YAP and TAZ
transcription co-activators: Key downstream effectors of the
mammalian Hippo pathway. Semin Cell Dev Biol. 23:785–793. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q
and Guan KL: Angiomotin is a novel Hippo pathway component that
inhibits YAP oncoprotein. Genes Dev. 25:51–63. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen HH, Maeda T, Mullett SJ and Stewart
AF: Transcription cofactor Vgl-2 is required for skeletal muscle
differentiation. Genesis. 39:273–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen HH, Mullett SJ and Stewart AF: Vgl-4,
a novel member of the vestigial-like family of transcription
cofactors, regulates alpha1-adrenergic activation of gene
expression in cardiac myocytes. J Biol Chem. 279:30800–30806. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Günther S, Mielcarek M, Kruger M and Braun
T: VITO-1 is an essential cofactor of TEF1-dependent
muscle-specific gene regulation. Nucleic Acids Res. 32:791–802.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Koontz LM, Liu-Chittenden Y, Yin F, Zheng
Y, Yu J, Huang B, Chen Q, Wu S and Pan D: The Hippo effector Yorkie
controls normal tissue growth by antagonizing scalloped-mediated
default repression. Dev Cell. 25:388–401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lamar JM, Stern P, Liu H, Schindler JW,
Jiang ZG and Hynes RO: The Hippo pathway target, YAP, promotes
metastasis through its TEAD-interaction domain. Proc Natl Acad Sci
USA. 109:E2441–E2450. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Knight JF, Shepherd CJ, Rizzo S, Brewer D,
Jhavar S, Dodson AR, Cooper CS, Eeles R, Falconer A, Kovacs G, et
al: TEAD1 and c-Cbl are novel prostate basal cell markers that
correlate with poor clinical outcome in prostate cancer. Br J
Cancer. 99:1849–1858. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lim B, Park JL, Kim HJ, Park YK, Kim JH,
Sohn HA, Noh SM, Song KS, Kim WH, Kim YS, et al: Integrative
genomics analysis reveals the multilevel dysregulation and
oncogenic characteristics of TEAD4 in gastric cancer.
Carcinogenesis. 35:1020–1027. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Y, Wang G, Yang Y, Mei Z, Liang Z, Cui
A, Wu T, Liu CY and Cui L: Increased TEAD4 expression and nuclear
localization in colorectal cancer promote epithelial-mesenchymal
transition and metastasis in a YAP-independent manner. Oncogene.
35:2789–2800. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schütte U, Bisht S, Heukamp LC, Kebschull
M, Florin A, Haarmann J, Hoffmann P, Bendas G, Buettner R, Brossart
P and Feldmann G: Hippo signaling mediates proliferation,
invasiveness, and metastatic potential of clear cell renal cell
carcinoma. Transl Oncol. 7:309–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou GX, Li XY, Zhang Q, Zhao K, Zhang CP,
Xue CH, Yang K and Tian ZB: Effects of the hippo signaling pathway
in human gastric cancer. Asian Pac J Cancer Prev. 14:5199–5205.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang DW, Sherman BT, Tan Q, Collins JR,
Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC and Lempicki
RA: The DAVID Gene Functional Classification Tool: A novel
biological module-centric algorithm to functionally analyze large
gene lists. Genome Biol. 8:R1832007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Edmondson HA and Steiner PE: Primary
carcinoma of the liver: A study of 100 cases among 48,900
necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ghassan K A-A and Timothy M: Pawlik,
Junichi Shindoh and Jean-Nicolas Vauthey editors: AJCC Cancer
Staging Manual. (Eighth ed). Chicago, IL: Springer; pp. 287–293.
2017
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen Z, Friedrich GA and Soriano P:
Transcriptional enhancer factor 1 disruption by a retroviral gene
trap leads to heart defects and embryonic lethality in mice. Genes
Dev. 8:2293–2301. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sawada A, Kiyonari H, Ukita K, Nishioka N,
Imuta Y and Sasaki H: Redundant roles of Tead1 and Tead2 in
notochord development and the regulation of cell proliferation and
survival. Mol Cell Biol. 28:3177–3189. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kaneko KJ, Kohn MJ, Liu C and DePamphilis
ML: Transcription factor TEAD2 is involved in neural tube closure.
Genesis. 45:577–587. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Holden JK and Cunningham CN: Targeting the
Hippo pathway and cancer through the TEAD family of transcription
factors. Cancers (Basel). 10(pii): E812018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang C, Nie Z, Zhou Z, Zhang H, Liu R, Wu
J, Qin J, Ma Y, Chen L, Li S, et al: The interplay between TEAD4
and KLF5 promotes breast cancer partially through inhibiting the
transcription of p27Kip1. Oncotarget. 6:17685–17697.
2015.PubMed/NCBI
|
|
26
|
Guo C, Wang X and Liang L: LATS2-mediated
YAP1 phosphorylation is involved in HCC tumorigenesis. Int J Clin
Exp Pathol. 8:1690–1697. 2015.PubMed/NCBI
|
|
27
|
Mao B, Hu F, Cheng J, Wang P, Xu M, Yuan
F, Meng S, Wang Y, Yuan Z and Bi W: SIRT1 regulates YAP2-mediated
cell proliferation and chemoresistance in hepatocellular carcinoma.
Oncogene. 33:1468–1474. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bai N, Zhang C, Liang N, Zhang Z, Chang A,
Yin J, Li Z, Luo N, Tan X, Luo N, et al: Yes-Associated Protein
(YAP) increases chemosensitivity of hepatocellular carcinoma cells
by modulation of p53. Cancer Biol Ther. 14:511–520. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sánchez-Tilló E, Liu Y, de Barrios O,
Siles L, Fanlo L, Cuatrecasas M, Darling DS, Dean DC, Castells A
and Postigo A: EMT-activating transcription factors in cancer:
Beyond EMT and tumor invasiveness. Cell Mol Life Sci. 69:3429–3456.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Diepenbruck M, Waldmeier L, Ivanek R,
Berninger P, Arnold P, van Nimwegen E and Christofori G: Tead2
expression levels control the subcellular distribution of Yap and
Taz, zyxin expression and epithelial-mesenchymal transition. J Cell
Sci. 127:1523–1536. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Allard WJ, Matera J, Miller MC, Repollet
M, Connelly MC, Rao C, Tibbe AG, Uhr JW and Terstappen LW: Tumor
cells circulate in the peripheral blood of all major carcinomas but
not in healthy subjects or patients with nonmalignant diseases.
Clin Cancer Res. 10:6897–6904. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
McDougall SR, Anderson AR and Chaplain MA:
Mathematical modelling of dynamic adaptive tumour-induced
angiogenesis: Clinical implications and therapeutic targeting
strategies. J Theor Biol. 241:564–859. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang W, Gao Y, Li P, Shi Z, Guo T, Li F,
Han X, Feng Y, Zheng C, Wang Z, et al: VGLL4 functions as a new
tumor suppressor in lung cancer by negatively regulating the
YAP-TEAD transcriptional complex. Cell Res. 24:331–343. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jiao S, Li C, Hao Q, Miao H, Zhang L, Li L
and Zhou Z: VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt
and Hippo signalling in colorectal cancer. Nat Commun. 8:140582017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jin HS, Park HS, Shin JH, Kim DH, Jun SH,
Lee CJ and Lee TH: A novel inhibitor of apoptosis protein
(IAP)-interacting protein, Vestigial-like (Vgl)-4, counteracts
apoptosis-inhibitory function of IAPs by nuclear sequestration.
Biochem Biophys Res Commun. 412:454–459. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jiao S, Wang H, Shi Z, Dong A, Zhang W,
Song X, He F, Wang Y, Zhang Z, Wang W, et al: A peptide mimicking
VGLL4 function acts as a YAP antagonist therapy against gastric
cancer. Cancer Cell. 25:166–180. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang Y, Shen H, Withers HG, Yang N,
Denson KE, Mussell AL, Truskinovsky A, Fan Q, Gelman IH, Frangou C
and Zhang J: VGLL4 Selectively represses YAP-dependent gene
induction and tumorigenic phenotypes in breast cancer. Sci Rep.
7:61902017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shu B, Zhai M, Miao X, He C, Deng C, Fang
Y, Luo M, Liu L and Liu S: Serotonin and YAP/VGLL4 balance
correlated with progression and poor prognosis of hepatocellular
carcinoma. Sci Rep. 8:97392018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xie W, Hao J, Zhang K, Fang X and Liu X:
Adenovirus armed with VGLL4 selectively kills hepatocellular
carcinoma with G2/M phase arrest and apoptosis promotion. Biochem
Biophys Res Commun. 503:2758–2763. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhou Y, Huang T, Cheng AS, Yu J, Kang W
and To KF: The TEAD family and its oncogenic role in promoting
tumorigenesis. Int J Mol Sci. 17(pii): E1382016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lin KC, Park HW and Guan KL: Regulation of
the Hippo pathway transcription factor TEAD. Trends Biochem Sci.
42:862–872. 2017. View Article : Google Scholar : PubMed/NCBI
|
